Model-informed drug development: Case studiesStockholm Uppsala Pharmacometrics meeting
Welcome to this afternoon which will showcase how modeling transforms clinical development decisions across modalities and therapeutic areas.
Talks will demonstrate models anchored in clinical data driving dose and schedule optimization, endpoint selection, patient enrichment, study designs, go/no-go, pediatric extrapolation, labeling, and postmarketing commitments. Content will span population PK/PD, exposure–response, disease progression, PBPK, QSP, and model-based meta-analysis. Case studies will highlight measurable impacts on decisions, timelines, cost, and probability of success.
For more information please visit the SUP meeting website.
Program
Meeting 13:00–17:00
Mingle with light food 17:00–19:00
Speakers
- Martin Bergstrand, Pharmetheus
- Probability of Pharmacological Success (PoPS) to inform First-In-Human (FIH) studies
- Mads Kreilgaard,NovoNordisk,
- Model-informed development of Mim8 – a novel bispecific antibody for the treatment of haemophilia A
- Yu-Jou Lin,Uppsala University
- An integrated PK-PD framework for dose optimization of bedaquiline in adults with tuberculosis”
- Zinnia P Parra-Guillen,BioInvent
- Utilizing a semi-mechanistic model linking PK, FcγRIIB receptor occupancy, and platelet dynamics to inform clinical development of BI-1206
- Sebastian Ueckert,Ribocure
- Using Public Data to Extrapolate Long-Term Treatment Response in HBV
Target audience
Academics and industry working in the field of clinical pharmacology, DMPK and pharmacometrics.
Tid & Plats
Thursday April 16
At 13:00 – 19:00
Welcome wishes the Section for Pharmacokinetics and drug metabolism together with Stockholm-Uppsala Pharmacometrics meeting!